- Home
- FCNCP vs SRPT Comparison
FCNCP vs SRPT Comparison
Compare FCNCP & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCNCP | SRPT |
|---|---|---|
| Founded | N/A | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.0B |
| IPO Year | 1995 | 2000 |
Fundamental Metrics
Financial Performance| Metric | FCNCP | SRPT |
|---|---|---|
| Price | $18.86 | $18.95 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 29 |
| Target Price | N/A | ★ $25.85 |
| AVG Volume (30 Days) | 11.9K | ★ 2.9M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 97.95 | 2.99 |
| Revenue | ★ $9,541,000,000.00 | $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $0.19 | $6.97 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $19.00 | $14.68 |
| 52 Week High | $22.60 | $25.32 |
Technical Indicators
Market Signals| Indicator | FCNCP | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout FCNCP First Citizens BancShares Inc.
First Citizens is a US regional bank with total assets of around $237 billion as of June 30, 2026. Headquartered in Raleigh, North Carolina, First Citizens' largest markets are North Carolina, South Carolina, and California. The bank has a track record of acquiring troubled banks from the FDIC, such as Silicon Valley Bridge Bank in 2023, which doubled its asset base. First Citizens offers products and services across retail, commercial, wealth management, and railcar leasing. First Citizens derived over 95% of its earnings from banking and less than 5% from railcar leasing in 2025.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.